Status:
COMPLETED
Predicting Response to Incretin Based Agents in Type 2 Diabetes
Lead Sponsor:
Royal Devon and Exeter NHS Foundation Trust
Collaborating Sponsors:
National Institute for Health Research, United Kingdom
University of Exeter
Conditions:
Type2 Diabetes
Eligibility:
All Genders
18+ years
Brief Summary
Type 2 diabetes is a major and rapidly increasing health problem worldwide. Keeping the blood glucose (sugar) from going too high helps prevent complications. Recently a number of new treatments (coll...
Eligibility Criteria
Inclusion
- A clinical diagnosis of type 2 diabetes mellitus where the patient's clinician has determined the need for a DPP-IV inhibitor or GLP-1 analogue as a result of inadequate glycaemic control
- HbA1c \>= 58mmol/mol
Exclusion
- Treatment with DPP-IV inhibitors or GLP-1 analogues prior to study initiation (within the previous 3 months)
- Renal failure as shown by a eGFR (estimated glomerular filtration rate) less than 30 mL/min/1.73m2
Key Trial Info
Start Date :
May 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
957 Patients enrolled
Trial Details
Trial ID
NCT01503112
Start Date
May 1 2011
End Date
April 1 2014
Last Update
April 19 2018
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Cornwall and Isles of Scilly NHS Primary Care Trust
Truro, Cornwall, United Kingdom, TR13HD
2
North Devon NHS Trust
Barnstaple, Devon, United Kingdom, EX314JB
3
Royal Devon and Exeter NHS Foundation Trust
Exeter, Devon, United Kingdom, EX25DW
4
Plymouth Hospitals NHS Trust
Plymouth, Devon, United Kingdom, PL68DH